ClinicalTrials.gg
Not yet recruitingNCT07841678Updated Sep 25, 2026

A Phase III Clinical Study of Jinpei Growth Hormone Injection in the Treatment of Short Stature Children With Small for Gestational Age (SGA)

A Phase 3 interventional study of PEG-hGH Injection and hGH Injection in Small for Gestational Age, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Newly registeredGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, open-label, active-controlled Phase III clinical study to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of once-weekly PEG-hGH injection compared with once-daily hGH injection in the treatment of prepubertal children with short stature due to small for gestational age (SGA) who have not received prior growth hormone treatment.

Eligible subjects will be randomized in a 2:1 ratio to receive either PEG-hGH injection 0.3 mg/kg/week (experimental group) or hGH injection 0.066 mg/kg/day (active comparator group) for 52 weeks, followed by a 52-week extension period in which all subjects receive PEG-hGH injection 0.3 mg/kg/week. The primary endpoint is annualized height velocity (AHV) at Week 52.

02

Conditions studied

  • Small for Gestational Age
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 111 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of small for gestational age (SGA), with birth certificate or discharge record; gestational age ≥28 weeks; birth weight and/or length below the 10th percentile (P10) for sex and gestational age.
  • Age ≥3 years at the time of (calculated from birth date on birth certificate/ID).
  • Prepubertal boys and girls (Tanner stage I).
  • Screening height \< -2 SD of normal height reference values for same sex and chronological age.
  • Screening bone age \< chronological age + 1 year (bone age X-ray within 6 months before screening acceptable).
  • No prior treatment with growth hormone, IGF-1, or insulin-like secretagogues.
  • Subject and guardian able to voluntarily sign informed consent form (ICF) and comply with study procedures; for subjects without civil capacity, guardian's written informed consent required, with subject assent when possible.

Exclusion criteria

Exclusion Criteria:

  • to growth hormone class drugs or their .
  • Suspected or confirmed pediatric growth hormone deficiency (GHD) requiring GH stimulation testing (GH peak >7 ng/mL excludes GHD).
  • Known chromosomal or gene mutations affecting growth, or known syndromes including but not limited to GHD, Turner syndrome, Laron syndrome, Noonan syndrome, Prader-Willi syndrome, Silver-Russell syndrome, skeletal dysplasia, SHOX gene abnormalities.
  • Any known or suspected disease/condition that may cause short stature and may interfere with endpoint evaluation, including but not limited to chronic kidney disease, diabetes, skeletal dysplasia (with family history), severe spinal abnormalities, malnutrition, hypothyroidism, immunodeficiency.
  • Current signs/symptoms of increased intracranial pressure, active proliferative retinopathy, or history of slipped capital femoral epiphysis or intracranial hypertension.
  • Cognitive impairment, neurodevelopmental disorder or psychiatric illness that may interfere with endpoint evaluation.
  • Current intracranial tumor, hematologic or other malignant tumor (regardless of treatment); family history of tumor or high tumor risk (e.g., Bloom syndrome, Fanconi syndrome, Down syndrome).
  • Positive at screening; history or diagnosis of , infection or tuberculosis.
  • Abnormal screening laboratory values considered by investigator to interfere with safety evaluation ( >1.5×; creatinine >1.5×ULN).
  • Screening indicates impaired fasting glucose, impaired glucose tolerance or diabetes.
  • Systemic treatment within 3 months before screening (>28 days cumulative or >14 days continuous).
  • Prior use of aromatase inhibitors, GnRH analogs, sex hormones, protein anabolic drugs, or other drugs affecting growth and development.
  • Unable to receive subcutaneous injections (e.g., anticoagulant therapy, bleeding disorders, idiopathic thrombocytopenic purpura).
  • Claustrophobia or inability to undergo head MRI.
  • Participation in other clinical trials within 3 months before screening.
  • Other conditions considered by investigator unsuitable for enrollmen.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    PEG-hGH Injection 0.3 mg/kg/week

    Subjects receive PEG-hGH injection at a dose of 0.3 mg/kg/week by subcutaneous injection, once weekly, for 52 weeks during the treatment period. In the extension period, all subjects continue to receive PEG-hGH injection 0.3 mg/kg/week for another 52 weeks.

    Drug: PEG-hGH Injection

  • Active comparator
    hGH Injection 0.066 mg/kg/day

    Subjects receive hGH injection at a dose of 0.066 mg/kg/day by subcutaneous injection, once daily, for 52 weeks during the treatment period. In the extension period, subjects switch to PEG-hGH injection 0.3 mg/kg/week for 52 weeks.

    Drug: hGH Injection

Interventions

  • DrugPEG-hGH Injection

    PEGylated recombinant human growth hormone (PEG-hGH) injection, trade name Jinsizeng. Dose: 0.3 mg/kg/week, subcutaneous injection, once weekly. Specification: 54 IU/9.0 mg/1.0 mL/vial. Administered via electronic pen injector.

  • DrughGH Injection

    Recombinant human growth hormone (hGH) injection, trade name Saizeng. Dose: 0.066 mg/kg/day, subcutaneous injection, once daily. Specification: 30 IU/10 mg/3 mL/vial. Administered via electronic pen injector.

06

What researchers measure

Primary outcomes

  1. Annualized Height Velocity (AHV)

    Time frame: Week 52

07

Study locations

1 site
08

References and documents

Publications

  • Luo X, Hou L, Zhong Y, Zhao S, Chen X, Dong Q, Du H, Lu H, Yang Y, Wu X, Luo F, Chen R, Xu Z, Ma Y, Song W, Feng M, Gu X, Qiu W. A Phase 2 Study of PEGylated Recombinant Human Growth Hormone for 52 Weeks in Short Children Born Small for Gestational Age in China. Clin Endocrinol (Oxf). 2025 Feb;102(2):136-146. doi: 10.1111/cen.15156. Epub 2024 Nov 8. PubMed 39513569 ↗
09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07841678
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Jan 2030 (estimated)
Last update
Sep 25, 2026

Study contacts

Xiaoping Luo
Contact
xpluo888@sina.com
+8613387522645
Ling Hou
Contact
houlingtj@163.com
+8613437131846

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion